Charles River Laboratories Inte (CRL) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $187.51: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: Below-average business quality.
Charles River Laboratories provides non-clinical drug development services across three segments — Discovery and Safety Assessment (59.8% of 2025 revenue), Research Models and Services (21.1%), and Manufacturing Solutions (19.1%) — generating $4.0 billion in total revenue in... Read more
Sell if holding. Engine safety override at $187.51: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: Below-average business quality. Chart setup: Death cross but MACD improving, RSI 70. Score 4.6/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — Charles River Laboratories Inte
Latest news
- NEWS 10 Health Care Stocks With Whale Alerts In Today's Session — benzinga Jun 1, 2026 neutral
- NEWS CLSA Upgrades Charles River to Outperform, Raises Price Target to $219 — benzinga May 29, 2026 positive
- NEWS Charles River And MEDIPOST Enter Into Strategic, Non-Exclusive MOU To Collaborate On GMP-Compliant Testing To Advance Ce — benzinga May 13, 2026 positive
- NEWS These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results — benzinga May 8, 2026 positive
- NEWS Barclays Maintains Overweight on Charles River, Raises Price Target to $220 — benzinga May 8, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductDSA segment60%10-K Item 1: 'our DSA segment represented 59.8% of our total revenue'
- MEDIUMSuppliernon-human primate supply10-K Item 1A: 'our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business'
Material Events(8-K, last 90d)
- 2026-05-11Item 5.02LOWShareholders approved the 2026 Long-Term Incentive Plan at the May 5, 2026 annual meeting. Board of Directors had adopted the plan on March 11, 2026 subject to shareholder approval. No officer departure cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -4.6%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $187.51: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: Below-average business quality. Chart setup: Death cross but MACD improving, RSI 70. Prior stop was $174.38. Score 4.6/10, moderate confidence.
Take-profit target: $191.04 (+1.9% upside). Prior stop was $174.38. Stop-loss: $174.38.
Concentration risk — Product: DSA segment (59.8%); Target reached (1.9% upside); Quality below floor (3.4 < 4.0).
Charles River Laboratories Inte trades at a P/E of N/A (forward 15.2). TrendMatrix value score: 7.1/10. Verdict: Sell.
24 analysts cover CRL with a consensus score of 4.0/5. Average price target: $212.
What does Charles River Laboratories Inte do?Charles River Laboratories provides non-clinical drug development services across three segments — Discovery and Safety...
Charles River Laboratories provides non-clinical drug development services across three segments — Discovery and Safety Assessment (59.8% of 2025 revenue), Research Models and Services (21.1%), and Manufacturing Solutions (19.1%) — generating $4.0 billion in total revenue in 2025 across 120+ sites in over 20 countries. The company serves pharmaceutical and biotechnology clients that outsource drug discovery and safety testing.